The small-molecule inhibitor of survivin, YM 155, has shown promise for the treatment of solid tumours and lymphoma

By  

Inpharma, Vol. 1, Iss. 1659, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma

By Kefford Richard   Beith Jane   Hazel Guy   Millward Michael   Trotter James   Wyld David   Kusic Rada   Shreeniwas Revati   Morganti Adele   Ballmer Andrea   Segal Eleonor   Nayler Oliver   Clozel Martine  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 247-252

Springer Publishing Company

Access to resources Recommend Favorite

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

By Hersh Evan   O’Day Steven   Powderly John   Khan Khuda   Pavlick Anna   Cranmer Lee   Samlowski Wolfram   Nichol Geoffrey   Yellin Michael   Weber Jeffrey  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 489-498

Springer Publishing Company

Access to resources Recommend Favorite

A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane

By Ajani J.   Safran H.   Bokemeyer C.   Shah M.   Lenz H.-J.   Cutsem E.   Burris H.   Lebwohl D.   Mullaney B.  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 441-446

Springer Publishing Company

Access to resources Recommend Favorite

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

By Ajani Jaffer   Jiang Yixing   Faust Josephine   Chang Baochong   Ho Linus   Yao James   Rousey Steven   Dakhil Shaker   Cherny Richard   Craig Catherine   Bleyer Archie  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 353-357

Springer Publishing Company

Access to resources Recommend Favorite